Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Comment by valentinemassonon Aug 10, 2020 1:39am
191 Views
Post# 31385848

RE:Let’s see if we picked the right COVID horse

RE:Let’s see if we picked the right COVID horse
gimmycash wrote: So far Sona in the lead by far with no revs only a test and a dream,will we be the first to report multi  million  dollar revenue.and where will the sp land if so.


IMO Sona is an anomaly. When $16 hit, that was a 160,000% increase from December 2019 when the Sp was one penny. Had and sold, albeit at a much lower share price than current. The volatility is reminiscent of pot stocks in the day. MIR, 400,000 plus shares are owned by insiders. For those that post here saying SZLS is late to the covid game, other covid sticks have popped, szls was never a covid company. They are busy proving they are masters in class of laboratory accuracy, building a new foundation with newfound partners and using the money generated by covid testing to launch Aristotle into the market place. We have bases in Toronto and Virginia, American interests have always leaned towards companies conducting business on American soil. Back to Sona, while their test holds promise, they have not submitted an application to the FDA pending completion of clinical trials. MIR has submitted, pending notification. The Sp at Sona is certainly able to see a run similar to TLRY a few years back, lesser shares out, thus the run from IPO of $17, to $300 in a matter of weeks. That said, BIO tech can have similar possibilities. Using stop losses and specifically trailing stop losses in stocks that are moving is a safe bet. It is my hope that James has seemingly turned a new leaf and at this stage of his career, can feel his time of being. To leave a legacy behind and a dramatic turnaround in a career that met many shortcomings, perhaps at times a victim of circumstance and much larger money controlling outcomes and thwarting ideals and dreams. Now is the time Mr. Tripp. And Mr. Tripp feels it. It is now time to shine. Good luck to us all. VM.
Bullboard Posts